A combination of isradipine and naltrexone blocks cocaine's enhancement of a cocaine place preference

Pharmacology Biochemistry and Behavior

Volumn 60, Issue 4, 1998, Pages 847-853

  Cramer, Christopher M ^a   Hubbell, Christopher L ^a   Reid, Larry D ^a  

^a RENSSELAER POLYTECHNIC INSTITUTE   (United States)

Author keywords

Addiction; Cocaine; Conditioned place preference; Isradipine; Naltrexone

Indexed keywords

COCAINE; ISRADIPINE; NALTREXONE; PLACEBO;

ANIMAL MODEL; ARTICLE; CONDITIONING; CONTROLLED STUDY; INTRAPERITONEAL DRUG ADMINISTRATION; LOCOMOTION; MALE; NARCOTIC DEPENDENCE; NONHUMAN; PLACE PREFERENCE; PRIORITY JOURNAL; RAT;

ANIMALIA;

EID: 0031828007     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-3057(98)00063-X     Document Type: Article

References (33)

1. Bain G., Kornetsky C. Naloxone attenuation of the effect of cocaine on rewarding brain stimulation. Life Sci. 40:1987;1119-1125.
2. Bain G.T., Kornetsky C. Opioids' modification of central reward processes. Reid L.D. Opioids, bulimia, and alcohol abuse & alcoholism. 1990;73-87 Springer Verlag, New York.
3. Bilsky E.J., Montegut M.J., Delong C.L., Reid L.D. Opioidergic modulation of cocaine place preference. Life Sci. 50:1992;85-90.
4. Bilsky, E. J.; Montegut, M. J.; Nichols, M. L.; Reid, L. D.: CGS 10746B, a novel dopamine release inhibitor, blocks the establishment of cocaine and MDMA conditioned place preference. Pharmacol. Biochem. Behav. (in press).
5. Boja J.W., Kopajtic T.A. Ion channel inhibitors may function as potential modulators of cocaine binding. Neuropharmacology. 32:1993;229-234.
6. Bozarth M.A. Conditioned place preference: A parametric analysis using systemic heroin injections. Bozarth M.A. Methods of assessing the reinforcing properties of abused drugs. 1987;241-273 Springer Verlag, New York.
7. Bozarth M.A. Methods of assessing the reinforcing properties of abused drugs. 1987;Springer Verlag, New York.
8. Brogden R.N., Sorkin E.M. Isradipine: An update of its phamacodynamic and pharmacokinetic properties an therapeutic efficacy in the treatment of mild to moderate hypertension. Drug Eval. 49:1985;618-649.
9. Calcagnetti D.J., Schechter M.D. Isradipine produces neither a conditioned place preference nor aversion. Life Sci. 54:1994;81-86.
10. Cramer, C. M.; Gardell, L. R.; Boedeker, K. L.; Harris, J. R.; Hubbell, C. L.; Reid, L. D.: Isradipine combined with naltrexone persistently reduces the reward-relevant effects of cocaine and alcohol. Pharmacol. Biochem. Behav. (in press).
11. Fulginiti S., Cancela L.M. Effects of naloxone and amphetamine on acquisition and memory consolidation of active avoidance responses in rats. Psychopharmacology (Berlin). 79:1983;45-48.
12. Gardell L.R., Reid L.D., Boedeker K.L., Liakos T.M., Hubbell C.L. Isradipine and isradipine in combination with naltrexone as pharmacotherapy for alcohol dependence. Alcohol. Clin. Exp. Res. 21:1997;1435-1439.
13. Gerrits M.A.F.M., Patkina N., Zvartau E.E., Van Ree J.M. Opioid blockade attenuates acquisition and expression of cocaine-induced place preference conditioning in rats. Psychopharmacology (Berlin). 119:1995;92-98.
14. Gonzales P.M., Boswell K.J., Hubbell C.L., Reid L.D. Isradipine blocks cocaine's ability to facilitate pressing for intracranial stimulation. Pharmacol. Biochem. Behav. 58:1997;1117-1122.
15. Holman B.L., Carvalho P.A., Mendelson J., Teoh S.K., Nardin R., Hallgring E., Hebben N., Johnson K.A. Brain perfusion is abnormal in cocaine-dependent polydrug users. A study using Technetium-99m-HMPAO and ASPECT J. Nucleic Med. 32:1991;1206-1210.
16. Judson B.A., Goldstein A. Naltrexone treatment of heroin addiction. One-year follow-up Drug Alcohol Depend. 13:1984;357-365.
17. Kosten T.R., Kleber H.D., Morgan C. Role of opioid antagonists in treating intravenous cocaine abuse. Life Sci. 44:1989;887-892.
18. Kuzmin A., Zvartau E., Gessa G.L., Martellotta M.C., Fratta W. Calcium antagonists isradipine and nimodipine suppress cocaine and morphine intravenous self-administration in drug-naive mice. Pharmacol. Biochem. Behav. 41:1992;497-500.
19. Martellotta M.C., Kuzmin A., Muglia P., Gessa G.L., Fratta W. Effects of the calcium antagonist isradipine on cocaine intravenous self-administration in rats. Psychopharmacology (Berlin). 113:1994;3778-3780.
20. O'Brien C.P., Volpicelli L.A., Volpicelli J.R. Naltrexone in the treatment of alcoholism. A clinical review Alcohol. 13:1996;35-39.
21. Pani L., Kuzmin A.V., Martellotta M.C., Gessa G.L., Fratta W. The calcium antagonist PN 200-110 inhibits the reinforcing properties of cocaine. Brain Res. Bull. 26:1991;445-447.
22. Reid L.D., Hubbell C.L., Glick S.D., Boswell K.J., Chen A.M., Moran C.M., Cramer C.M., Mullen U.D., Chambers M.D., Gonzales P.M., Irizarry K.L., Amendola C.A. Initial analyses of naltriben, a delta opioid receptor antagonist, as a putative medicine for treating cocaine abuse. Exp. Clin. Psychopharmacol. 4:1996;271-284.
23. Reid L.D., Marglin S.H., Mattie M.E., Hubbell C.L. Measuring morphine's capacity to establish a place preference. Pharmacol. Biochem. Behav. 33:1989;765-775.
24. Reid L.D., Pabello N.G., Cramer C.M., Hubbell C.L. Isradipine in combination with naltrexone as a medicine for treating cocaine abuse. Life Sci. 60:1997;PL119-PL126.
25. Reid, L. D.; Pabello, N. G.; Gardell, L. R.; Cramer, C. M.; Hubbell, C. L.: Isradipine and naltrexone in combination as a medicine for polydrug abuse. Paper presented at the annual meeting of the International Behavioral Neuroscience Society, San Diego, CA, April 1997.
26. Rossi N.A., Reid L.D. Affective states associated with morphine injections. Physiol. Psychol. 4:1976;269-274.
27. Schechter M.D., Calcagnetti D.J. Trends in place preference conditioning with a cross-indexed bibliography; 1957-91. Neurosci. Biobehav. Rev. 17:1993;21-41.
28. Spivey W.H., Euerle B. Neurologic complications of cocaine abuse. Ann. Emerg. Med. 19:1990;1422-1428.
29. 2-methionine enkephalin. Physiol. Psychol. 7:1979;146-152.
30. Tazi A., Farh M., Hakkou F. Behavioral effects of a calcium channel antagonist. Nifedipine Fundam. Clin. Pharmacol. 5:1991;229-236.
31. Tumeh S.S., Nagel J.S., English R.J., Moore M., Holman B.L. Cerebral abnormalities in cocaine abusers. Demonstration by SPECT perfusion brain scintigraphy Radiology. 176:1990;821-824.
32. Volkow N.D., Mullani N., Gould K.L., Adler S., Krajewski K. Cerebral blood flow in chronic cocaine users. A study with positron emission tomography Br. J. Psychiatry. 152:1988;641-648.
33. Wolkowitz O.M., Tinklenberg J.R., Weingartner H. A psychopharmacological perspective of cognitive functions. II. Specific pharmacological agents. Neuropsychobiology. 14:1985;133-156.